Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 1:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 76 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Coronary Artery Disease Risk High Clear all
Completed Phase 3 Interventional

A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG

NCT00402506
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury
Interventions
(MC-1) Pyridoxal 5'-phosphate
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 16, 2007 · Synced Oct 11, 2026, 1:13 PM EDT
Completed Not applicable Interventional Results available

XIENCE 28 USA Study

NCT03815175
View directory record Official record
Conditions
Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases, Thrombocytopenia, Coagulation Disorder, Anemia, Renal Insufficiency, Coronary Artery Disease
Interventions
XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
54
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Oct 11, 2026, 1:13 PM EDT
Completed Not applicable Interventional Results available

Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64

NCT00488033
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
CT Angiography
Procedure
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 11, 2026, 1:13 PM EDT
Completed No phase listed Observational

High-Sensitivity Cardiac Troponin T to OPtimize Chest Pain Risk Stratification

NCT02984436
View directory record Official record
Conditions
Acute Coronary Syndrome, Chest Pain
Interventions
Blood Sample, HEART Score
Procedure · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
21 Years and older
Enrollment
1,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Sacramento, California • Gainesville, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 11, 2026, 1:13 PM EDT
Active, not recruiting Not applicable Interventional

Reducing Blood Pressure in Patients With High Cardiovascular Risk

NCT05937685
View directory record Official record
Conditions
Myocardial Infarction, Hypertension, Stroke
Interventions
BP REACH Intervention
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
35 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Downey, California • Los Angeles, California • Sylmar, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 11, 2026, 1:13 PM EDT
Terminated Not applicable Interventional Results available

SHIELD II Clinical Investigation

NCT02468778
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
HeartMate PHP, Any Abiomed Impella® device approved for use in high-risk PCI
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
58
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 11, 2026, 1:13 PM EDT
Active, not recruiting Not applicable Interventional

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

NCT01047735
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 11, 2026, 1:13 PM EDT
Completed No phase listed Observational

Risk-score Based ICU Triage

NCT03390270
View directory record Official record
Conditions
Non-ST Elevation Myocardial Infarction (nSTEMI)
Interventions
Admission with NSTEMI
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 11, 2026, 1:13 PM EDT
Active, not recruiting Not applicable Interventional

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

NCT04763200
View directory record Official record
Conditions
Left Ventricular Dysfunction, Coronary Artery Disease
Interventions
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 11, 2026, 1:13 PM EDT
Recruiting Phase 3 Interventional

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

NCT07613294
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
Interventions
Lepodisiran, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
17
States / cities
La Jolla, California • Northridge, California • Torrance, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 11, 2026, 1:13 PM EDT
Not listed Phase 3 Interventional

Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

NCT04806893
View directory record Official record
Conditions
Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Stroke, Hypercholesterolemia
Interventions
lerodalcibep, Placebo
Drug · Other
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 11, 2026, 1:13 PM EDT
Completed Not applicable Interventional

Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care

NCT01983813
View directory record Official record
Conditions
Diabetes Mellitus, Hypertension, Coronary Artery Disease, Atrial Fibrillation, Stroke
Interventions
PHCVRS Intervention, Personal Health Record
Other
Lead sponsor
Korey Kennelty
Other
Eligibility
50 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
Akron, Iowa • Belmond, Iowa • Cedar Rapids, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 11, 2026, 1:13 PM EDT
Completed Not applicable Interventional

Early Feasibility Study of the Supira System in Patients Undergoing HRPCI

NCT06087575
View directory record Official record
Conditions
Coronary Artery Disease, High-risk Percutaneous Coronary Intervention, Interventional Cardiology
Interventions
Supira System
Device
Lead sponsor
Supira Medical
Industry
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Sacramento, California • Atlanta, Georgia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 11, 2026, 1:13 PM EDT
Completed Phase 1 Interventional

Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease

NCT02370680
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Aspirin, Durlaza™
Drug
Lead sponsor
New Haven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Oct 11, 2026, 1:13 PM EDT
Active, not recruiting Not applicable Interventional

LEADERS FREE II: BioFreedom™ Pivotal Study

NCT02843633
View directory record Official record
Conditions
Acute Coronary Syndrome, High Bleeding Risk
Interventions
BioFreedom™ Drug Coated Coronary Stent System, Antiplatelet Drug
Device · Drug
Lead sponsor
Biosensors Europe SA
Industry
Eligibility
Not listed
Enrollment
1,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
39
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 11, 2026, 1:13 PM EDT
Completed No phase listed Observational

The WOMEN Study: What is the Optimal Method for Ischemia Evaluation in WomeN?

NCT00282711
View directory record Official record
Conditions
Coronary Artery Disease, Heart Disease, Coronary Arteriosclerosis, Cardiovascular Disease, Myocardial Ischemia
Interventions
Not listed
Lead sponsor
Hartford Hospital
Other
Eligibility
60 Years and older · Female only
Enrollment
824 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
41
States / cities
Tucson, Arizona • Anaheim, California • Escondido, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 11, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)

NCT00414609
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Aliskiren, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Novartis US, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 13, 2012 · Synced Oct 11, 2026, 1:13 PM EDT
Completed Not applicable Interventional

Latinos Understanding the Need for Adherence

NCT02955238
View directory record Official record
Conditions
Atherosclerosis, High Blood Pressure, Type 2 Diabetes Mellitus, Heart Disease, Hypercholesterolemia
Interventions
Special Intervention
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
40 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 11, 2026, 1:13 PM EDT
Terminated Phase 2 Interventional Results available

SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy

NCT03606642
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Stent Placement
Interventions
Dual Antiplatelet (DAPT) Therapy, The Synergy® stent
Drug · Device
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
75 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 11, 2026, 1:13 PM EDT
Completed Phase 4 Interventional Results available

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)

NCT00790907
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
3,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Ocala, Florida • Albuquerque, New Mexico • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 11, 2026, 1:13 PM EDT
Terminated Phase 3 Interventional Results available

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

NCT01975376
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
bococizumab (PF-04950615), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
545
States / cities
Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 339 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 11, 2026, 1:13 PM EDT
Recruiting Phase 4 Interventional

The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk

NCT05152888
View directory record Official record
Conditions
Stable Coronary Disease
Interventions
Evolocumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 11, 2026, 1:13 PM EDT
Recruiting Phase 4 Interventional

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

NCT07025148
View directory record Official record
Conditions
Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 11, 2026, 1:13 PM EDT
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 11, 2026, 1:13 PM EDT